AUA 2011 - Clusterin antisense inhibitor OGX-011 synergizes activity of second generation anti-androgen, MDV3100, in castrate resistant prostate cancer model - Session Highlights
AUA 2011 - Consistency of tumor position on repeat prostate biopsy in men on active surveillance for prostate cancer-implications for hemiablation - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Using biopsy data from active surveillance (AS) patients, these investigators importantly show that prostate hemiablation should not rely on one set of prostate biopsies for adequate tumor localization and characterization.
AUA 2011 - Differential expression of RANKL and osteoprotegerin in patients with clinically localized prostate cancer - Session Highlights
WASHINGTON, DC USA (UroToday.com) - According to this fascinating report, there is suggestion that localized prostate cancer may initiate osteolytic bone activity well before clinically apparent bone metastasis from prostate cancer occur.
AUA 2011 - Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality - Session Highlights
WASHINGTON, DC USA (UroToday.com) - A positive surgical margin (PSM) alone does not negatively affect 15-year prostate cancer-specific mortality (PCSM) in this multi-institutional report.
AUA 2011 - Implications of surgical margin status on prostate cancer-specific survival - Session Highlights
WASHINGTON, DC USA (UroToday.com) - This important presentation reports that in a multivariable analysis a positive surgical margin (PSM) is an independent predictor of prostate cancer-specific mortality (PCSM).
AUA 2011 - Inhibition of prostate cancer progression by dutasteride and the impact on anxiety, quality of life, and urinary symptoms in men undergoing active surveillance: REDEEM study results - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Men on active surveillance (AS) for prostate cancer who were treated with dutasteride had less anxiety and better QOL according to Dr. Fleshner and colleagues in this talk.
AUA 2011 - Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer - Session Highlights
WASHINGTON, DC USA (UroToday.com) - While tyrosine kinase inhibitors (TKIs) are undergoing testing in patients with castration-resistant prostate cancer (CRPC), there previously has been no biomarker to predict response.
AUA 2011 - John Duckett Memorial Lecture: Urology in 2040 - what will it look like? - Session Highlights
AUA 2011 - Long term results of immediate versus deferred androgen deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891) - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Immediate compared with deferred androgen deprivation therapy results in a modest increase in overall survival but no significant difference in prostate cancer mortality according to this update from the EORTC Trial 30891.
AUA 2011 - Meat and related meat mutagen consumption and risk of advanced prostate cancer - Session Highlights
WASHINGTON, DC USA (UroToday.com) - A fish sandwich rather than a well-cooked hamburger might decrease the risk of advanced prostate cancer according to this report!
AUA 2011 - Neuropeptides promote castration resistant prostate cancer through intracrine androgen biosynthesis - Session Highlights
WASHINGTON, DC USA (UroToday.com) - This presentation is the first report that neuropeptides can activate prostate cancer intracrine androgen biosynthesis and that the process is partially blocked by a Src kinase inhibitor.
AUA 2011 - Panel discussion: Conflicting guidelines for the treatment of vesicoureteral reflux - Session Highlights
WASHINGTON, DC USA (UroToday.com) - The pediatric VUR guidelines have been recently revised but are currently not available.
AUA 2011 - Pediatrics: Andrology – cryptorchidism and varicoceles - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Lymphatic sparing varicocele repair in the pediatric population significantly lowers the incidence of postoperative hydrocele.
AUA 2011 - Phase 1-2 study of MDV3100 in pre-and post-docetaxel advanced prostate cancer: long-term efficacy results - Session Highlights
WASHINGTON, DC USA (UroToday.com) - This presentation provides long-term efficacy results from the initial MDV3100 phase I-II trial. It suggests that the antitumor activity of MDV3100 is of long duration.
AUA 2011 - Pre-operative urinary prostate cancer gene 3 (PCA3) is predicting pathologically confirmed small volume and insignificant prostate cancer - Session Highlights
WASHINGTON, DC USA (UroToday.com) - This presentation in a cohort of US-European patients suggests that the Prostate CAncer Gene 3 (PCA3) score may help identify pathologically insignificant prostate cancer (ICaP) and thus prove complementary to existing criteria for selecting patients for active surveillance.
AUA 2011 - Regional availability of proton beam therapy and variation in treatment for men with low risk prostate cancer in California - Session Highlights
WASHINGTON, DC USA (UroToday.com) - A patient with prostate cancer is more likely to get proton beam therapy if he lives in the vicinity of a center that has one, according to this report.
AUA 2011 - RRP as stand-alone therapy for high-risk prostate cancer - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Dr. Steven Joniau presented multi-institutional data that among select patients with high-risk prostate cancer (CaP), surgery alone has good outcomes.
AUA 2011 - Smoking and adverse outcomes at radical prostatectomy - Session Highlights
WASHINGTON, DC USA (UroToday.com) - This study has made an important link between smoking and prostate cancer.
AUA 2011 - State of the art lecture: Fetal urologic intervention report card - valves, myelomeningocele and congenital hyperplasia - Session Highlights
WASHINGTON, DC USA (UroToday.com) - Dr. Brock reviewed the current status of prenatal intervention for these 3 conditions.